Allogene Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Allogene Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $4.00K.
- Allogene Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Allogene Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Allogene Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Allogene Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Allogene Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $813.00K, a 61.04% decline from fiscal 2023.
- Allogene Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $2.09M, a 326.79% increase from fiscal 2022.
- Allogene Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $489.00K, a 94.14% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $4.00K 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | |
| 2024-12-31 | $813.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $19.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $794.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $2.09M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $326.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.61M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $489.00K 10-K/A · filed 2024-03-14 | |
| 2022-09-30 | $135.00K 10-Q · filed 2023-11-02 | $766.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $25.00K 10-Q · filed 2023-11-02 | $1.38M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $283.00K 10-Q · filed 2023-11-02 | $4.57M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $323.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $8.35M 10-K/A · filed 2024-03-14 |
| 2021-09-30 | $750.00K 10-Q · filed 2022-11-02 | $9.61M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-06-30 | $3.21M 10-Q · filed 2022-11-02 | $11.31M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-03-31 | $4.06M 10-Q · filed 2022-11-02 | $12.57M derived: sum of 4 quarters · filed 2024-03-14 |
| 2020-12-31 | $1.59M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $8.81M 10-K/A · filed 2024-03-14 |
| 2020-09-30 | $2.45M 10-Q · filed 2021-11-04 | $9.48M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $4.48M 10-Q · filed 2021-08-04 | $7.50M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $303.00K 10-Q · filed 2021-05-05 | $3.26M derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $2.96M 10-K · filed 2022-02-23 |
| 2019-09-30 | $467.00K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $237.00K 10-Q · filed 2020-08-05 | |
| 2018-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $5.00K 10-K · filed 2021-02-25 |
| 2018-09-30 | $3.00K 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $1.00K 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |